These Analysts Boost Their Forecasts On MiniMed Group Following Q1 Sales Results

Benzinga Earnings

Sep 02

MiniMed Group Inc (NASDAQ:MMED) on Tuesday reported better-than-expected first-quarter sales results.

Minimed Group reported quarterly sales of $843.000 million which beat the analyst consensus estimate of $827.065 million, representing a 16.6% increase over sales of $723.000 million in the year-ago period.

“MiniMed delivered an excellent start to our fiscal year, with accelerating U.S. growth, continued double-digit international growth, and strong execution across our innovation pipeline,” said MiniMed Chief Executive Officer Que Dallara. “The U.S. launch of MiniMed Flex™ is doing exactly what we designed it to do: bringing new patients into the MiniMed ecosystem, driving competitive conversions, and generating significant new account growth. As our ecosystem continues to come together, we are well positioned to accelerate growth, strengthen our leadership in automated insulin delivery, and create long-term shareholder value.”

MiniMed shares jumped 7.1% to trade at $24.01 on Wednesday.

These analysts made changes to their price targets on MiniMed following the announcement.

B of A Securities analyst Travis Steed maintained the stock with a Buy and raised the price target from $24 to $28.
Mizuho analyst Anthony Petrone maintained the stock with an Outperform rating and raised the price target from $21 to $26.
UBS analyst Patrick Wood maintained the stock with a Buy and boosted the price target from $25 to $28.

Considering buying MMED stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/news/2664481796"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2664481796\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2664481796?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-02 22:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2664481796","market":"hk","top_or_hot":-1,"title":"These Analysts Boost Their Forecasts On MiniMed Group Following Q1 Sales Results","media":"Benzinga Earnings","content":"<html><body><p><strong>MiniMed Group Inc</strong> (NASDAQ:MMED) on Tuesday reported better-than-expected first-quarter sales results.</p>\n<p>Minimed Group reported quarterly sales of $843.000 million which beat the analyst consensus estimate of $827.065 million, representing a 16.6% increase over sales of $723.000 million in the year-ago period.</p>\n<p>“MiniMed delivered an excellent start to our fiscal year, with accelerating U.S. growth, continued double-digit international growth, and strong execution across our innovation pipeline,” said MiniMed Chief Executive Officer Que Dallara. “The U.S. launch of MiniMed Flex™ is doing exactly what we designed it to do: bringing new patients into the MiniMed ecosystem, driving competitive conversions, and generating significant new account growth. As our ecosystem continues to come together, we are well positioned to accelerate growth, strengthen our leadership in automated insulin delivery, and create long-term shareholder value.”</p>\n<p>MiniMed shares jumped 7.1% to trade at $24.01 on Wednesday.</p>\n<p>These analysts made changes to their price targets on MiniMed following the announcement.</p>\n<ul>\n<li>B of A Securities analyst Travis Steed maintained the stock with a Buy and raised the price target from $24 to $28.</li>\n<li>Mizuho analyst Anthony Petrone maintained the stock with an Outperform rating and raised the price target from $21 to $26.</li>\n<li>UBS analyst Patrick Wood maintained the stock with a Buy and boosted the price target from $25 to $28.</li>\n</ul>\n<p><strong>Considering buying MMED stock? Here’s what analysts think:</strong></p>\n<figure><img decoding=\"async\" height=\"299\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/09/02101758/image-63-1024x299.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/09/02101758/image-63-1024x299.png 1024w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/09/02101758/image-63-300x88.png 300w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/09/02101758/image-63-768x224.png 768w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/09/02101758/image-63.png 1170w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These Analysts Boost Their Forecasts On MiniMed Group Following Q1 Sales Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese Analysts Boost Their Forecasts On MiniMed Group Following Q1 Sales Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga Earnings </p>\n<p class=\"h-time\">2026-09-02 22:18</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong>MiniMed Group Inc</strong> (NASDAQ:MMED) on Tuesday reported better-than-expected first-quarter sales results.</p>\n<p>Minimed Group reported quarterly sales of $843.000 million which beat the analyst consensus estimate of $827.065 million, representing a 16.6% increase over sales of $723.000 million in the year-ago period.</p>\n<p>“MiniMed delivered an excellent start to our fiscal year, with accelerating U.S. growth, continued double-digit international growth, and strong execution across our innovation pipeline,” said MiniMed Chief Executive Officer Que Dallara. “The U.S. launch of MiniMed Flex™ is doing exactly what we designed it to do: bringing new patients into the MiniMed ecosystem, driving competitive conversions, and generating significant new account growth. As our ecosystem continues to come together, we are well positioned to accelerate growth, strengthen our leadership in automated insulin delivery, and create long-term shareholder value.”</p>\n<p>MiniMed shares jumped 7.1% to trade at $24.01 on Wednesday.</p>\n<p>These analysts made changes to their price targets on MiniMed following the announcement.</p>\n<ul>\n<li>B of A Securities analyst Travis Steed maintained the stock with a Buy and raised the price target from $24 to $28.</li>\n<li>Mizuho analyst Anthony Petrone maintained the stock with an Outperform rating and raised the price target from $21 to $26.</li>\n<li>UBS analyst Patrick Wood maintained the stock with a Buy and boosted the price target from $25 to $28.</li>\n</ul>\n<p><strong>Considering buying MMED stock? Here’s what analysts think:</strong></p>\n<figure><img decoding=\"async\" height=\"299\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/09/02101758/image-63-1024x299.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/09/02101758/image-63-1024x299.png 1024w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/09/02101758/image-63-300x88.png 300w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/09/02101758/image-63-768x224.png 768w, https://editorial-assets.benzinga.com/wp-content/uploads/2026/09/02101758/image-63.png 1170w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MMED","symbol_name":"MiniMed Group, Inc.","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/09/61577250/these-analysts-boost-their-forecasts-on-minimed-group-following-q1-sales-results","article_id":"2664481796","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2664481796","pubTimestamp":1788358738,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga Earnings","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"MiniMed Group beat Q1 sales estimates with 16.6% growth to $843M; shares rose 7.1% as analysts raised price targets to $26-$28.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"MMED":"MiniMed Group, Inc."},"translate_title":"这些分析师在第一季度销售业绩公布后上调了对 MiniMed Group 的预测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MMED":1.5},"content_text":"MiniMed Group Inc (NASDAQ:MMED) on Tuesday reported better-than-expected first-quarter sales results.\nMinimed Group reported quarterly sales of $843.000 million which beat the analyst consensus estimate of $827.065 million, representing a 16.6% increase over sales of $723.000 million in the year-ago period.\n“MiniMed delivered an excellent start to our fiscal year, with accelerating U.S. growth, continued double-digit international growth, and strong execution across our innovation pipeline,” said MiniMed Chief Executive Officer Que Dallara. “The U.S. launch of MiniMed Flex™ is doing exactly what we designed it to do: bringing new patients into the MiniMed ecosystem, driving competitive conversions, and generating significant new account growth. As our ecosystem continues to come together, we are well positioned to accelerate growth, strengthen our leadership in automated insulin delivery, and create long-term shareholder value.”\nMiniMed shares jumped 7.1% to trade at $24.01 on Wednesday.\nThese analysts made changes to their price targets on MiniMed following the announcement.\n\nB of A Securities analyst Travis Steed maintained the stock with a Buy and raised the price target from $24 to $28.\nMizuho analyst Anthony Petrone maintained the stock with an Outperform rating and raised the price target from $21 to $26.\nUBS analyst Patrick Wood maintained the stock with a Buy and boosted the price target from $25 to $28.\n\nConsidering buying MMED stock? Here’s what analysts think:\n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}